{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:35:43Z","timestamp":1771472143617,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a serious complication which is associated with increased mortality. The RenalGuard system was developed to reduce the risk of AKI after contrast media exposition by furosemide-induced diuresis with matched isotonic intravenous hydration. The aim of this study was to examine the effect of the RenalGuard system on the occurrence of AKI after TAVI in patients with chronic kidney disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The present study is a single-center randomized trial including patients with severe aortic valve stenosis undergoing TAVI. Overall, a total of 100 patients treated by TAVI between January 2017 and August 2018 were randomly assigned to a periprocedural treatment with the RenalGuard system or standard treatment by pre- and postprocedural intravenous hydration. Primary endpoint was the occurrence of AKI after TAVI, and secondary endpoints were assessed according to valve academic research consortium 2 criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, the prevalence of AKI was 18.4% (<jats:italic>n\u2009=\u2009<\/jats:italic>18). The majority of these patients developed mild AKI according to stage 1. Comparing RenalGuard to standard therapy, no significant differences were observed in the occurrence of AKI (RenalGuard: 21.3%; control group: 15.7%; <jats:italic>p\u2009=\u2009<\/jats:italic>0.651). In addition, there were no differences between the groups with regard to 30-day and 12-month mortality and procedure-associated complication rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-023-02234-z","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T17:02:17Z","timestamp":1685638937000},"page":"801-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-1854","authenticated-orcid":false,"given":"Lisa","family":"Voigtl\u00e4nder-Buschmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schmidt-Lauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Shenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Giraldo Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr Mariusz","family":"Kuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Twerenbold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Schofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Reichenspurner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenard","family":"Conradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2234_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.acvd.2014.01.002","volume":"107","author":"Y Elhmidi","year":"2014","unstructured":"Elhmidi Y, Bleiziffer S, Deutsch MA et al (2014) Acute kidney injury after transcatheter aortic valve implantation: Incidence, predictors and impact on mortality. Arch Cardiovasc Dis 107:133\u2013139","journal-title":"Arch Cardiovasc Dis"},{"key":"2234_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ndt\/gfy264","volume":"35","author":"O Kliuk-Ben Bassat","year":"2020","unstructured":"Kliuk-Ben Bassat O, Finkelstein A, Bazan S et al (2020) Acute kidney injury after transcatheter aortic valve implantation and mortality risk - Long-term follow-up. Nephrol Dial Transpl 35:433\u2013438. https:\/\/doi.org\/10.1093\/ndt\/gfy264","journal-title":"Nephrol Dial Transpl"},{"key":"2234_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7326\/0003-4819-148-4-200802190-00007","volume":"148","author":"AM Kelly","year":"2008","unstructured":"Kelly AM, Dwamena B, Cronin P et al (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:284\u2013294","journal-title":"Ann Intern Med"},{"key":"2234_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000066641","author":"HS Trivedi","year":"2003","unstructured":"Trivedi HS, Moore H, Nasr S et al (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. https:\/\/doi.org\/10.1159\/000066641","journal-title":"Nephron Clin Pract"},{"key":"2234_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ccd.26551","volume":"88","author":"SS Naidu","year":"2016","unstructured":"Naidu SS, Aronow HD, Box LC et al (2016) SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia intervencionista; affirmation of value by the Canadian Association. Catheter Cardiovasc Interv 88:407\u2013423. https:\/\/doi.org\/10.1002\/ccd.26551","journal-title":"Catheter Cardiovasc Interv"},{"key":"2234_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/joic.12417","volume":"30","author":"S Mattathil","year":"2017","unstructured":"Mattathil S, Ghumman S, Weinerman J, Prasad A (2017) Use of the RenalGuard system to prevent contrast-induced AKI: a meta-analysis. J Interv Cardiol 30:480\u2013487. https:\/\/doi.org\/10.1111\/joic.12417","journal-title":"J Interv Cardiol"},{"key":"2234_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.111.030759","volume":"124","author":"C Briguori","year":"2011","unstructured":"Briguori C, Visconti G, Focaccio A et al (2011) Renal insufficiency after contrast media administration trial II (REMEDIAL II). Circulation 124:1260\u20131269. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030759","journal-title":"Circulation"},{"key":"2234_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/J.JCIN.2011.08.017","volume":"5","author":"G Marenzi","year":"2012","unstructured":"Marenzi G, Ferrari C, Marana I et al (2012) Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv 5:90\u201397. https:\/\/doi.org\/10.1016\/J.JCIN.2011.08.017","journal-title":"JACC Cardiovasc Interv"},{"key":"2234_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jcin.2015.07.012","volume":"8","author":"M Barbanti","year":"2015","unstructured":"Barbanti M, Gulino S, Capranzano P et al (2015) Acute kidney injury with the RenalGuard system in patients undergoing transcatheter aortic valve replacement: the PROTECT-TAVI TRIAL (prophylactic effect of furosemide-induced diuresis with matched isotonic intravenous hydration in transcatheter aortic valve implantation). JACC Cardiovasc Interv 8:1595\u20131604. https:\/\/doi.org\/10.1016\/j.jcin.2015.07.012","journal-title":"JACC Cardiovasc Interv"},{"key":"2234_CR10","doi-asserted-by":"publisher","first-page":"e1658","DOI":"10.4244\/EIJV11I14A317","volume":"11","author":"G Visconti","year":"2016","unstructured":"Visconti G, Focaccio A, Donahue M et al (2016) RenalGuard system for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention 11:e1658\u2013e1661. https:\/\/doi.org\/10.4244\/EIJV11I14A317","journal-title":"EuroIntervention"},{"key":"2234_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jjcc.2015.02.007","volume":"66","author":"K Chatani","year":"2015","unstructured":"Chatani K, Abdel-Wahab M, W\u00fcbken-Kleinfeld N et al (2015) Acute kidney injury after transcatheter aortic valve implantation: Impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up. J Cardiol 66:514\u2013519. https:\/\/doi.org\/10.1016\/j.jjcc.2015.02.007","journal-title":"J Cardiol"},{"key":"2234_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.1","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) (2012) Clinical practice guideline for acute kidney injury. Kidney Int Suppl. https:\/\/doi.org\/10.1038\/kisup.2012.1","journal-title":"Kidney Int Suppl"},{"key":"2234_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jtcvs.2012.09.002","volume":"145","author":"AP Kappetein","year":"2013","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P et al (2013) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg 145:6\u201323. https:\/\/doi.org\/10.1016\/j.jtcvs.2012.09.002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2234_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/J.AJKD.2019.05.031","volume":"75","author":"ED Siew","year":"2020","unstructured":"Siew ED, Abdel-Kader K, Perkins AM et al (2020) Timing of recovery from moderate to severe AKI and the risk for future loss of kidney function. Am J Kidney Dis 75:204\u2013213. https:\/\/doi.org\/10.1053\/J.AJKD.2019.05.031","journal-title":"Am J Kidney Dis"},{"key":"2234_CR15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"2234_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1053\/j.jvca.2016.12.021","volume":"31","author":"J Wang","year":"2017","unstructured":"Wang J, Yu W, Zhou Y et al (2017) Independent risk factors contributing to acute kidney injury according to updated Valve Academic Research Consortium-2 criteria after transcatheter aortic valve implantation: a meta-analysis and meta-regression of 13 studies. J Cardiothorac Vasc Anesth 31:816\u2013826. https:\/\/doi.org\/10.1053\/j.jvca.2016.12.021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2234_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ijcard.2012.10.029","volume":"168","author":"F Saia","year":"2013","unstructured":"Saia F, Ciuca C, Taglieri N et al (2013) Acute kidney injury following transcatheter aortic valve implantation: Incidence, predictors and clinical outcome. Int J Cardiol 168:1034\u20131040. https:\/\/doi.org\/10.1016\/j.ijcard.2012.10.029","journal-title":"Int J Cardiol"},{"key":"2234_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2215\/CJN.06480612","volume":"8","author":"N Pannu","year":"2013","unstructured":"Pannu N, James M, Hemmelgarn B, Klarenbach S (2013) Article association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin J Am Soc Nephrol 8:194\u2013202. https:\/\/doi.org\/10.2215\/CJN.06480612","journal-title":"Clin J Am Soc Nephrol"},{"key":"2234_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/J.AMJCARD.2018.01.049","volume":"121","author":"VJ Nijenhuis","year":"2018","unstructured":"Nijenhuis VJ, Peper J, Vorselaars VMM et al (2018) Prognostic value of improved kidney function after transcatheter aortic valve implantation for aortic stenosis. Am J Cardiol 121:1239\u20131245. https:\/\/doi.org\/10.1016\/J.AMJCARD.2018.01.049","journal-title":"Am J Cardiol"},{"key":"2234_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2459\/JCM.0000000000000348","volume":"17","author":"T Usmiani","year":"2016","unstructured":"Usmiani T, Andreis A, Budano C et al (2016) AKIGUARD (Acute Kidney Injury Guarding Device) trial: in-hospital and one-year outcomes. J Cardiovasc Med (Hagerstown) 17:530\u2013537. https:\/\/doi.org\/10.2459\/JCM.0000000000000348","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2234_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1161\/CIRCINTERVENTIONS.112.971291\/-\/DC1","volume":"5","author":"RJ Nuis","year":"2012","unstructured":"Nuis RJ, Rod\u00e9s-Cabau J, Sinning JM et al (2012) Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv 5:680\u2013688. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.112.971291\/-\/DC1","journal-title":"Circ Cardiovasc Interv"},{"key":"2234_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3978\/J.ISSN.2072-1439.2015.06.14","volume":"7","author":"M Scherner","year":"2015","unstructured":"Scherner M, Wahlers T (2015) Acute kidney injury after transcatheter aortic valve implantation. J Thorac Dis 7:1527. https:\/\/doi.org\/10.3978\/J.ISSN.2072-1439.2015.06.14","journal-title":"J Thorac Dis"},{"key":"2234_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/KI.2011.41","volume":"80","author":"E Singer","year":"2011","unstructured":"Singer E, Elger A, Elitok S et al (2011) Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int 80:405\u2013414. https:\/\/doi.org\/10.1038\/KI.2011.41","journal-title":"Kidney Int"},{"key":"2234_CR24","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/J.JCIN.2022.05.036","volume":"15","author":"S Mauler-Wittwer","year":"2022","unstructured":"Mauler-Wittwer S, Sievert H, Ioppolo AM et al (2022) Study evaluating the use of renalguard to protect patients at high risk of AKI. Cardiovasc Interv 15:1639\u20131648. https:\/\/doi.org\/10.1016\/J.JCIN.2022.05.036","journal-title":"Cardiovasc Interv"},{"key":"2234_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004383","author":"D Giacoppo","year":"2017","unstructured":"Giacoppo D, Gargiulo G, Buccheri S et al (2017) Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004383","journal-title":"Circ Cardiovasc Interv"},{"key":"2234_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/S00392-020-01732-8","volume":"110","author":"M Morcos","year":"2021","unstructured":"Morcos M, Burgdorf C, Vukadinivikj A et al (2021) Kidney injury as post-interventional complication of TAVI. Clin Res Cardiol 110:313\u2013322. https:\/\/doi.org\/10.1007\/S00392-020-01732-8","journal-title":"Clin Res Cardiol"},{"key":"2234_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMOA1912846","volume":"382","author":"D-H Kang","year":"2020","unstructured":"Kang D-H, Park S-J, Lee S-A et al (2020) Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med 382:111\u2013119. https:\/\/doi.org\/10.1056\/NEJMOA1912846","journal-title":"N Engl J Med"},{"key":"2234_CR28","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1093\/EURHEARTJ\/EHAA485","volume":"41","author":"H Baumgartner","year":"2020","unstructured":"Baumgartner H, Iung B, Otto CM (2020) Timing of intervention in asymptomatic patients with valvular heart disease. Eur Heart J 41:4349\u20134356. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAA485","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02234-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02234-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:04:33Z","timestamp":1716275073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02234-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02234-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS reports personal fees and non-financial support from Abbott Vascular, personal fees from Abiomed, personal fees from AstraZeneca, grants, personal fees and non-financial support from Boston Scientific, personal fees from Bristol-Myers Squibb, personal fees and non-financial support from Edwards Lifesciences, personal fees from Medtronic, personal fees from Amgen, personal fees from Shockwave Medical, personal fees from Daichii Sankyo, personal fees from Pfizer, personal fees from Siemens Healthineers, personal fees from Inari Medical, outside the submitted work. NS received travel support from Edwards Lifesciences and St. Jude Medical, speaker honoria and travel support from Boston Scientific. AS received speaking honoraria from Abbott. LC is a consultant and proctor for Edwards Lifesciences, Boston Scientific and Abbott and member of the speaker\u2019s bureau for Edwards Lifesciences, Boston Scientific, Abbott and Medtronic. US is a consultant and proctor for Edwards Lifesciences, Boston Scientific, New Valve Technology\/Biosensors, Medtronic, and Abbott Vascular and member of the speaker\u2019s bureau for Edwards Lifesciences, Boston Scientific, New Valve Technology\/Biosensors, Abbott Vascular and Medtronic. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}